Figure 2From: PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataTrial design of the ‘NeoPHOEBE’ trial with two identical cohorts and upfront PIK3CA genotyping to ensure adequate power for both mutant and wild-type cohorts. HER2, human epidermal growth factor receptor 2.Back to article page